Related Experiment Video
Updated: Jan 19, 2026

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Association study identified biologically relevant receptor genes with synergistic functions in celiac disease
Pratibha Banerjee1, Sandilya Bhagavatula1, Ajit Sood2
1Department of Human Genetics and Molecular Medicine, School of Health Sciences, Central University of Punjab, Bathinda, Punjab, India.
Abstract:
Receptors are essential mediators of cellular physiology, which facilitate molecular and cellular cross-talk with the environment. Nearly 20% of the all known celiac disease (CD) genes are receptors by function. We hypothesized that novel biologically relevant susceptibility receptor genes act in synergy in CD pathogenesis. We attempted to identify novel receptor genes in CD by re-analyzing published Illumina Immunochip dense genotype data for a north Indian and a European (Dutch) cohort. North Indian dataset was screened for 269 known receptor genes. Association statistics for SNPs were considered with minor allele frequency >15% and association P ≤ 0.005 to attend desired study power. Identified markers were tested for cross-ethnic replication in a European CD dataset. Markers were analyzed in-silico to explain their functional significance in CD. Six novel SNPs from MOG (rs29231, p = 1.21e-11), GABBR1 (rs3025643, p = 1.60e-7), OR2H2 (rs1233388, p = 0.0002), ABCF1 (rs9262119, p = 0.0005), ADRA1A (rs10102024, p = 0.003), and ACVR2A (rs7560426, p = 0.004) were identified in north Indians, of which three genes namely, GABBR1 (rs3025643, p = 5.38e-8), OR2H2 (rs1233388, p = 3.29e-5) and ABCF1 (rs9262119, p = 0.0002) were replicated in Dutch. Tissue specific functional annotation, potential epigenetic regulation, co-expression, protein-protein interaction and pathway enrichment analyses indicated differential expression and synergistic function of key genes that could alter cellular homeostasis, ubiquitination mediated phagosome pathway and cellular protein processing to contribute for CD. At present multiple therapeutic compounds/drugs are available targeting GABBR1 and ADRA1A, which could be tested for their effectiveness against CD in controlled drug trials.
Insights
Researchers identified novel receptor genes associated with celiac disease (CD) by analyzing genetic data from North Indian and European cohorts. Three genes, GABBR1, OR2H2, and ABCF1, were replicated, suggesting potential therapeutic targets for CD.
Area of Science:
- Genetics
- Immunology
- Cellular Biology
Background:
- Receptors are crucial for cell communication and environmental interaction.
- Approximately 20% of known celiac disease (CD) genes encode receptors.
- The study hypothesizes that novel susceptibility receptor genes act synergistically in CD pathogenesis.
Purpose of the Study:
- To identify novel receptor genes associated with celiac disease (CD).
- To investigate the synergistic function of these genes in CD pathogenesis.
- To explore potential therapeutic targets for CD based on identified genes.
Main Methods:
- Re-analysis of published Illumina Immunochip genotype data from North Indian and European (Dutch) cohorts.
- Screening of 269 known receptor genes in the North Indian dataset with specific criteria for single nucleotide polymorphisms (SNPs).
- In-silico analysis including tissue-specific functional annotation, epigenetic regulation, co-expression, protein-protein interaction, and pathway enrichment.
Main Results:
- Six novel SNPs in MOG, GABBR1, OR2H2, ABCF1, ADRA1A, and ACVR2A were identified in North Indians.
- Three genes, GABBR1, OR2H2, and ABCF1, showed cross-ethnic replication in the Dutch cohort.
- Functional analyses suggested differential expression and synergistic functions impacting cellular homeostasis and protein processing in CD.
Conclusions:
- Identified GABBR1, OR2H2, and ABCF1 as novel potential susceptibility genes for celiac disease.
- These genes may contribute to CD through altered cellular homeostasis and protein processing pathways.
- Existing drugs targeting GABBR1 and ADRA1A warrant investigation for CD treatment.
More Related Videos
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10:27Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011